Helicobacter Pylori H Pylori Non-Invasive Testing Market
Report ID: SQMIG35A4154
Report ID: SQMIG35A4154
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A4154 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
172
|Figures:
79
Global Helicobacter Pylori H Pylori Non-Invasive Testing Market size was valued at USD 0.95 Billion in 2024 and is poised to grow from USD 1.02 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
The global helicobacter pylori H pylori non‑invasive testing industry encompasses diagnostic kits that detect the bacterium through stool antigen, urea‑breath, and serology methods without endoscopic sampling. Its importance drives from H. pylori’s link to peptic ulcers, gastric cancer, and dyspepsia, conditions that demand early, cost‑effective identification. A primary driver has been the worldwide shift toward outpatient care, where clinicians prefer tools over invasive endoscopy.
Over the decade, stool‑antigen assays gained traction in Europe after reimbursement policies favored them, while urea‑breath tests expanded in North America following FDA clearances. These trends illustrate the market’s evolution from laboratory products to modern diagnostic staples. Another pivotal factor shaping the market is the integration of non‑invasive tests into antimicrobial stewardship programs, which reduces unnecessary antibiotic use and curtails resistance. When a stool‑antigen result is negative, physicians can safely defer empiric therapy, thereby lowering drug expenditures and adverse event rates. Health systems in Japan have adopted this approach, reporting a 15 % drop in clarithromycin prescriptions after testing was mandated. The cost advantage of breath‑test platforms also encourages clinics to offer screening, expanding access in rural regions and generating revenue streams for device manufacturers. Consequently, the convergence of clinical guidelines, payer incentives, and portability fuels market expansion.
How is AI improving the accuracy of Helicobacter pylori H pylori non‑invasive testing market?
AI is reshaping helicobacter pylori non invasive testing by turning raw diagnostic signals into clearer clinical decisions. Machine learning models can sift through breath test carbon isotope ratios or stool antigen optical densities, spotting subtle patterns that traditional thresholds miss. This reduces false negatives and false positives, giving clinicians more confidence in a single test result. Real time analytics also allow laboratories to flag borderline cases for repeat testing before results reach the patient. By linking test outputs with electronic health records, AI helps personalize follow up recommendations and streamlines referral pathways. The combined effect is higher diagnostic accuracy, faster turnaround and broader adoption of non invasive methods across primary care.
BioMérieux in May 2023, introduced an AI enhanced interpretation engine for its Helicobacter pylori stool antigen assay, allowing automated pattern analysis that sharpens result precision. The tool speeds reporting and reduces operator bias, reinforcing confidence in non invasive testing and driving broader market uptake.
Market snapshot - (2026-2033)
Global Market Size
USD 0.95 Billion
Largest Segment
Urea Breath Tests
Fastest Growth
Molecular Tests (PCR-Based)
Growth Rate
7.4% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global helicobacter pylori H pylori non-invasive testing market is segmented by test type, technology, application, end user, patient type, product type and region. Based on test type, the market is segmented into Urea Breath Tests, Stool Antigen Tests, Serology Tests and Molecular Tests (PCR-Based). Based on technology, the market is segmented into Immunoassays, Molecular Diagnostics and Breath Analysis Technologies. Based on application, the market is segmented into Initial Diagnosis, Post-Treatment Monitoring and Screening Programs. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Clinics and Point-of-Care Settings. Based on patient type, the market is segmented into Pediatric and Adult. Based on product type, the market is segmented into Test Kits & Reagents, Instruments & Analyzers and Consumables. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Urea breath tests segment dominates with large helicobacter pylori H pylori non-invasive testing market share because clinicians prioritize a rapid, highly specific diagnostic tool that directly measures active infection without invasive procedures. The breath‑based approach aligns with patient preference for convenience and reduces procedural risk, fostering widespread adoption across hospitals and outpatient clinics. Its ability to provide same‑day results simplifies treatment decisions, reinforcing its position as the preferred first‑line option for Helicobacter pylori detection.
As per global helicobacter pylori H pylori non-invasive testing market outlook, stool antigen tests emerge as the most rapidly expanding area within the non‑invasive Helicobacter pylori market. Their suitability for pediatric and adult screening, combined with low infrastructure requirements, drives adoption in primary care and community health programs. This convenience fuels broader testing coverage, creating new avenues for market growth.
As per global helicobacter pylori H pylori non-invasive testing market forecast, immunoassays segment leads because they offer a mature, cost‑effective platform that integrates easily into existing laboratory workflows. The reliability of antibody‑based detection, combined with simple equipment needs, makes them attractive for both high‑volume hospitals and smaller diagnostic labs. Their established regulatory pathways and extensive clinical validation reinforce confidence, ensuring they remain the backbone of non‑invasive Helicobacter pylori testing across diverse care settings.
As per global helicobacter pylori H pylori non-invasive testing market analysis, molecular diagnostics is witnessing the strongest growth momentum in the Helicobacter pylori non‑invasive testing market. Advances in PCR sensitivity enable precise detection of bacterial DNA from stool, appealing to clinicians seeking results. Growing confidence in molecular accuracy and decreasing platform costs accelerate adoption, expanding market reach into care settings.
To get detailed segments analysis, Request a Free Sample Report
Asia Pacific dominates the global helicobacter pylori H pylori non-invasive testing market owing to a confluence of advanced healthcare infrastructure, proactive government initiatives, and a high prevalence of gastric disorders that drive demand for convenient diagnostics. Nations such as Japan and South Korea have swiftly integrated breath and stool assays into routine clinical pathways, supported by strong reimbursement policies and extensive laboratory networks. The region benefits from robust research ecosystems that foster rapid development of high‑sensitivity assays, while a culture of early disease detection encourages widespread screening across both urban and rural populations. Together, these factors create a fertile environment for market leaders to expand product portfolios and cement the region’s leadership in non‑invasive H. pylori diagnostics.
As per global helicobacter pylori H pylori non-invasive testing market regional outlook, Japan benefits from strong research infrastructure and early adoption of advanced diagnostic platforms. Healthcare providers prioritize patient comfort, leading to preference for breath and stool assays over endoscopic procedures. Reimbursement frameworks support routine screening, especially in ageing populations with gastrointestinal concerns. Collaborative networks between academic institutions and device manufacturers accelerate innovation, reinforcing market momentum and clinical confidence and driving sustained growth globally.
As per global helicobacter pylori H pylori non-invasive testing market regional forecast, South Korea leverages a highly connected healthcare ecosystem and strong government emphasis on early disease detection. Clinicians favor non‑invasive assays for their ease of use, enabling widespread screening in community clinics. Robust insurance coverage reduces out‑of‑pocket barriers, encouraging routine testing for at‑risk groups. Partnerships between biotech firms and university hospitals foster continual refinement of assay sensitivity, reinforcing confidence among practitioners and market.
The rapid expansion of helicobacter pylori H pylori non-invasive testing market in North America is propelled by heightened clinical emphasis on patient comfort, extensive insurance coverage, and strong innovation pipelines that deliver ever‑more user‑friendly assays. Health systems prioritize non‑invasive diagnostics to streamline care pathways, reducing reliance on invasive endoscopy. Collaborative research between academic centers and commercial partners accelerates improvements in test accuracy, while public health campaigns raise awareness of H. pylori’s role in gastrointestinal disease. This supportive environment, combined with robust reimbursement structures, encourages clinicians to adopt breath and stool testing as first‑line tools, fueling sustained market growth across the United States and Canada.
As per global helicobacter pylori H pylori non-invasive testing industry analysis, United States benefits from extensive diagnostic laboratory networks and strong advocacy for evidence‑based screening protocols. Payers widely cover breath and stool assays, encouraging clinicians to adopt non‑invasive methods for both initial diagnosis and treatment verification. Ongoing research collaborations between leading gastroenterology centers and assay developers refine test performance, while patient education campaigns raise awareness of infection risks, collectively sustaining robust market activity.
Canada is supported by healthcare coverage that integrates breath and stool testing into routine primary care pathways. Provincial health authorities emphasize early detection to reduce treatment costs, encouraging widespread adoption of non‑invasive assays. Collaborative research programmes between Canadian universities and diagnostic firms enhance assay sensitivity, while public health messaging highlights the importance of screening, driving steady demand across urban and clinical settings.
Europe strengthens its position in market through coordinated regulatory frameworks, strong clinical guideline endorsement, and a focus on preventive gastrointestinal care. The European Union harmonizes approval processes for breath and stool assays, facilitating rapid market entry across member states. National health services prioritize non‑invasive diagnostics to reduce endoscopic burden, aligning with cost‑containment strategies. Leading research institutions collaborate with assay manufacturers to advance test accuracy and multiplexing capabilities. Public health campaigns raise awareness of H. pylori infection risks, encouraging routine screening in both primary and specialist settings, while cross‑border reimbursement agreements further support consistent adoption throughout the region.
Germany benefits from a robust health insurance system that reimburses breath and stool tests as standard diagnostic tools. Clinical practice guidelines strongly recommend non‑invasive screening for at‑risk patients, driving widespread utilization. Partnerships between German biotech firms and academic hospitals foster continuous improvement of assay sensitivity, while government‑funded research initiatives support validation studies, reinforcing confidence among gastroenterologists and primary care providers in Europe.
United Kingdom is propelled by NHS policies that integrate breath and stool testing into primary care pathways for early detection. Clinical guidelines prioritize non‑invasive methods to streamline patient management and reduce endoscopic referrals. Collaborative projects between UK research universities and diagnostics companies accelerate assay innovation, while public awareness initiatives emphasize health benefits of screening, fostering steady demand across hospitals and community clinics.
France is reinforced by a national health insurance scheme that reimburses breath and stool tests as diagnostics. French gastroenterology societies champion non‑invasive screening in their clinical recommendations, driving adoption in hospital and outpatient settings. Joint research initiatives with biotech firms focus on improving assay robustness, while education campaigns highlight the advantages of early detection, sustaining consistent demand throughout the French healthcare system.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Prevalence of H Pylori
Advancements In Molecular Testing Techniques
High Cost Of Advanced Kits
Regulatory Hurdles In Emerging Markets
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape is shaped by major diagnostics firms accelerating non‑invasive Helicobacter pylori solutions through strategic acquisitions, cross‑border partnerships, and rapid tech integration; Abbott’s purchase of a molecular‑assay specialist expands its breath‑test portfolio, BioMérieux’s alliance with a digital health platform accelerates point‑of‑care stool antigen kits, and Siemens Healthineers leverages AI‑driven analytics to enhance test accuracy, intensifying market rivalry and driving innovation cycles.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis the global non‑invasive H pylori testing market growth is being propelled primarily by the rising prevalence of H pylori infections, which pushes clinicians toward rapid, patient‑friendly diagnostics, a second strong catalyst is the rapid advancement of molecular testing techniques that deliver higher sensitivity and faster turnaround. The market is restrained by the high cost of advanced kits and instrumentation, which limits adoption in budget‑constrained facilities. Asia‑Pacific leads the market due to robust healthcare infrastructure, supportive reimbursement and high disease burden, while urea‑breath tests dominate the segment landscape because they offer same‑day, highly specific results for active infection. The global non-invasive H pylori testing market trend driven by increasing demand for early detection of gastrointestinal infections, rising awareness about the link between H pylori infection and gastric disorders, and the growing preference for patient-friendly diagnostic methods.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 0.95 Billion |
| Market size value in 2033 | USD 1.81 Billion |
| Growth Rate | 7.4% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Helicobacter Pylori H Pylori Non-Invasive Testing Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Helicobacter Pylori H Pylori Non-Invasive Testing Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Helicobacter Pylori H Pylori Non-Invasive Testing Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Helicobacter Pylori H Pylori Non-Invasive Testing Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Helicobacter Pylori H Pylori Non-Invasive Testing Market size was valued at USD 0.95 Billion in 2024 and is poised to grow from USD 1.02 Billion in 2025 to USD 1.81 Billion by 2033, growing at a CAGR of 7.4% during the forecast period (2026-2033).
The competitive landscape is shaped by major diagnostics firms accelerating non‑invasive Helicobacter pylori solutions through strategic acquisitions, cross‑border partnerships, and rapid tech integration; Abbott’s purchase of a molecular‑assay specialist expands its breath‑test portfolio, BioMérieux’s alliance with a digital health platform accelerates point‑of‑care stool antigen kits, and Siemens Healthineers leverages AI‑driven analytics to enhance test accuracy, intensifying market rivalry and driving innovation cycles. 'Danaher Corporation', 'Abbott Laboratories', 'F. Hoffmann-La Roche Ltd.', 'Thermo Fisher Scientific Inc.', 'bioMérieux SA', 'QIAGEN N.V.', 'Siemens Healthineers AG', 'QuidelOrtho Corporation', 'Meridian Bioscience, Inc.', 'SEKISUI Diagnostics, LLC', 'Trinity Biotech plc', 'DiaSorin S.p.A.', 'SD Biosensor, Inc.', 'Shenzhen Mindray Bio-Medical Electronics Co., Ltd.', 'CerTest Biotec S.L.', 'Coris BioConcept SPRL', 'Hangzhou AllTest Biotech Co., Ltd.', 'CTK Biotech, Inc.', 'Biohit Oyj', 'Jiangsu Macro & Micro-Test Med-Tech Co., Ltd.'
Healthcare providers are witnessing a steady rise in H pylori infections across diverse populations, prompting clinicians to seek reliable, patient‑friendly diagnostic alternatives. Non‑invasive tests, offering rapid results without endoscopic procedures, align with clinical priorities of minimizing discomfort and reducing procedural risks. Consequently, physicians increasingly recommend these assays as first‑line tools, driving demand among laboratories and hospitals. This heightened clinical adoption fuels commercial expansion, encourages product innovation, and supports broader market penetration across both established and emerging healthcare settings globally today.
Digital Health Integration: The rapid adoption of digital health platforms is reshaping how clinicians order and interpret H. pylori non‑invasive tests. Cloud‑based laboratory information systems enable real‑time result transmission, while mobile apps allow patients to receive notifications and educational content directly on their devices. This seamless connectivity reduces turnaround time, improves patient compliance, and facilitates longitudinal data collection for population‑level insights, driving broader acceptance of stool antigen and breath test modalities across primary‑care networks and strengthening interdisciplinary collaboration among gastroenterology, primary care, and public health stakeholders.
Why does Asia Pacific Dominate the Global Helicobacter Pylori H Pylori Non-Invasive Testing Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
